HH 120
Alternative Names: HH-120Latest Information Update: 13 Oct 2023
At a glance
- Originator Huahui Health
- Class Antivirals; Recombinant fusion proteins
- Mechanism of Action Viral fusion protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III COVID 2019 infections
Most Recent Events
- 31 Mar 2023 Phase-III clinical trials in COVID-2019 infections (Prevention) in China (Inhalation) (NCT05787418)
- 31 Mar 2023 Huahui Health plans a phase III trial for COVID-2019 infections (In adults, In the elderly) in China (Inhalation) (NCT05787418)
- 06 Feb 2023 Huahui Health in collaboration with Beijing Ditan Hospital completes a clinical trial in COVID-2019 infections (Prevention) in China (Inhalation) (NCT05747677)